Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q07001
UPID:
ACHD_HUMAN
Alternative names:
-
Alternative UPACC:
Q07001; A8K661; B4DT92; Q52LH4
Background:
The Acetylcholine receptor subunit delta plays a pivotal role in neuromuscular signaling, facilitating communication between nerve cells and muscles. This receptor is integral for muscle contraction, responding to acetylcholine by undergoing extensive conformational changes that open an ion-conducting channel across the plasma membrane.
Therapeutic significance:
Mutations in the Acetylcholine receptor subunit delta are linked to several forms of congenital myasthenic syndrome and lethal multiple pterygium syndrome, diseases characterized by muscle weakness and developmental abnormalities. Understanding the receptor's function and its genetic variants offers a pathway to targeted treatments for these neuromuscular disorders.